Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure with Preserved Ejection Fraction

Circulation: Heart Failure

Volumn 8, Issue 3, 2015, Pages 533-541

  Borlaug, Barry A ^a   Lewis, Gregory D ^b   McNulty, Steven E ^b   Semigran, Marc J ^c   Lewinter, Martin ^d   Chen, Horng ^a   Lin, Grace ^a   Deswal, Anita ^e   Margulies, Kenneth B ^f   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

diastolic heart failure; heart failure; vascular function; ventricular function

Indexed keywords

PLACEBO; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; VASODILATOR AGENT;

AGED; ARTERIAL ELASTANCE; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE ASSESSMENT; CELL FUNCTION; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG MEGADOSE; ELASTICITY; ENDOTHELIUM; FEMALE; HEART AFTERLOAD; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LOW DRUG DOSE; MALE; PEAK POWER INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; REACTIVE HYPEREMIA INDEX; SPHYGMOMANOMETER; STROKE WORK INDEX; SYSTEMIC VASCULAR RESISTANCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ARTERIAL PRESSURE; CLINICAL TRIAL; DRUG EFFECTS; EXERCISE TOLERANCE; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HYPEREMIA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ARTERIAL PRESSURE; ENDOTHELIUM, VASCULAR; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; SILDENAFIL CITRATE; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 84942936387     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001915     Document Type: Article

References (34)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. doi: 10.1056/NEJMoa052256.
2. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854. doi: 10.1016/j.jacc.2010.03.077.
3. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54:402-409. doi: 10.1016/j.jacc.2009.05.012.
4. Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, Frenneaux M, Sanderson JE. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009;54:36-46. doi: 10.1016/j.jacc.2009.03.037.
5. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595. doi: 10.1161/CIRCHEARTFAILURE.109.930701.
6. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol. 2010;56:855-863. doi: 10.1016/j.jacc.2010.04.040.
7. Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58:265-274. doi: 10.1016/j.jacc.2011.02.055.
8. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-515. doi: 10.1038/nrcardio.2014.83.
9. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679. doi: 10.1093/eurheartj/ehq426.
10. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
11. van Heerebeek L, Hamdani N, Falcaõ-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839. doi: 10.1161/CIRCULATIONAHA.111.076075.
12. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. doi: 10.1161/CIRCULATIONAHA.107.716373.
13. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. doi: 10.1161/CIRCULATIONAHA.106.626226.
14. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17. doi: 10.1161/CIRCHEARTFAILURE.110.944694.
15. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144. doi: 10.1016/j.jacc.2007.07.078.
16. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174. doi: 10.1161/CIRCULATIONAHA.110.983866.
17. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
18. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, Deswal A, Hernandez AF, Lee KL, Braunwald E; Heart Failure Clinical Research Network. PhosphdiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5:653-659. doi: 10.1161/CIRCHEARTFAILURE.112.969071.
19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. doi: 10.1016/j. echo.2005.10.005.
20. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005;112:2642-2649. doi: 10.1161/CIRCULATIONAHA.105.540500.
21. Sharir T, Feldman MD, Haber H, Feldman AM, Marmor A, Becker LC, Kass DA. Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power. Validation and noninvasive application. Circulation. 1994;89:2045-2053.
22. Nakayama M, Chen CH, Nevo E, Fetics B, Wong E, Kass DA. Optimal preload adjustment of maximal ventricular power index varies with cardiac chamber size. Am Heart J. 1998;136:281-288. doi: 10.1053/hj.1998.v136.89584.
23. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990. doi: 10.1161/CIRCULATIONAHA.106.659763.
24. Borlaug BA, Olson TP, Abdelmoneim Mohamed S, Melenovsky V, Sorrell VL, Noonan K, Lin G, Redfield MM. A randomized pilot study of aortic waveform guided therapy in chronic heart failure. J Am Heart Assoc. 2014;3:e000745. doi: 10.1161/JAHA.113.000745.
25. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
26. Haykowsky MJ, Herrington DM, Brubaker PH, Morgan TM, Hundley WG, Kitzman DW. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci. 2013;68:161-167. doi: 10.1093/gerona/gls099.
27. Hundley WG, Bayram E, Hamilton CA, Hamilton EA, Morgan TM, Darty SN, Stewart KP, Link KM, Herrington DM, Kitzman DW. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol. 2007;292:H1427-H1434. doi: 10.1152/ajpheart.00567.2006.
28. Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS, Levy D, Mitchell GF, Vita JA, Benjamin EJ. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension. 2011;57:390-396. doi: 10.1161/HYPERTENSIONAHA.110.160812.
29. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388-398. doi: 10.1161/01.RES.0000088351.58510.21.
30. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation. 2007;115:2159-2167. doi: 10.1161/CIRCULATIONAHA.106.643536.
31. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Bénardeau A, Mercadier JJ, Fischmeister R. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest. 1997;99:2710-2718. doi: 10.1172/JCI119460.
32. Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation. 1995;92:2198-2203.
33. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248. doi: 10.1161/CIRCULATIONAHA.106.655266.
34. Boilson BA, Schirger JA, Borlaug BA. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution. Eur J Heart Fail. 2010;12:89-93. doi: 10.1093/eurjhf/hfp171.